Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

May was a slightly negative month performance-wise for both BB Biotech and the overall biotech sector. SARS-CoV-2 remains a focus area for investors and Moderna has indeed been the biggest positive contributor to BB Biotech´s portfolio performance in 2021. Biotech markets have struggled year-to-date in comparison to equity markets in general. However, with the approval of Biogen´s Aducanumab for the treatment of Alzheimer´s disease on June 7th this could potentially be a driver for a more positive sentiment in the biotech sector.

BB Biotech Update May 2021

May was a slightly negative month performance-wise for both BB Biotech and the overall biotech sector. SARS-CoV-2 remains a focus area for investors and Moderna has indeed been the biggest positive contributor to BB Biotech´s portfolio performance in 2021. Biotech markets have struggled year-to-date in comparison to equity markets in general. However, with the approval of Biogen´s Aducanumab for the treatment of Alzheimer´s disease on June 7th this could potentially be a driver for a more positive sentiment in the biotech sector.
05.05.2021 - BB Biotech